European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live08-29

European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.56% to 1,476.60 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and medical device maker EDAP TMS (EDAP), which rose 5.1% and 3.3%, respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and internet browser company Opera (OPRA), which were up 2.3%, each.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Cellectis (CLLS), which fell 2% and 1.7%, respectively. They were followed by telecommunications company VEON (VEON) and electronics company Philips (PHG), which were down 0.9% each.

From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm (TCBP) and NuCana (NCNA), which advanced 20% and 7.2%, respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and software firm Endava (DAVA), which increased 4.1% and 3%.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which lost 6.5% and 1.9%, respectively. They were followed by utilities company National Grid (NGG) and insurance company Prudential (PUK), which dropped 1.3% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment